SIRT1 directly regulates SOX2 to maintain self-renewal and multipotency in bone marrow-derived mesenchymal stem cells

Stem Cells

Volumn 32, Issue 12, 2014, Pages 3219-3231

  Yoon, Dong Suk ^a,b   Choi, Yoorim ^a,b   Jang, Yeonsue ^a   Lee, Moses ^a   Choi, Woo Jin ^a   Kim, Sung Hwan ^a   Lee, Jin Woo ^a,b  

^a Yonsei University College of Medicine   (South Korea)

^b Yonsei University   (South Korea)

Author keywords

Acetylation; Bone marrow mesenchymal stem cells; Multipotency; Self renewal; SIRT1; SOX2

Indexed keywords

CYCLIN A; CYCLIN D; CYCLIN DEPENDENT KINASE 2; KRUPPEL LIKE FACTOR 4; RESVERATROL; SIRTUIN 1; TRANSCRIPTION FACTOR NANOG; TRANSCRIPTION FACTOR SOX2; TRICHOSTATIN A; SIRT1 PROTEIN, HUMAN; SOX2 PROTEIN, HUMAN; TRANSCRIPTION FACTOR SOX;

ADIPOGENESIS; ARTICLE; BONE DEVELOPMENT; BONE MARROW DERIVED MESENCHYMAL STEM CELL; BONE MINERALIZATION; CELL DIFFERENTIATION; CELL POPULATION; CELL RENEWAL; COLONY FORMING UNIT; CONTROLLED STUDY; DEACETYLATION; GENE OVEREXPRESSION; GENE REPRESSION; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; PROTEIN ACETYLATION; PROTEIN DEGRADATION; PROTEIN LOCALIZATION; PROTEIN PROCESSING; REGULATORY MECHANISM; RNA INTERFERENCE; UBIQUITINATION; ADULT; BONE MARROW; BONE MARROW CELL; CELL PROLIFERATION; CELL SELF-RENEWAL; CYTOLOGY; GENETICS; MESENCHYMAL STROMA CELL; METABOLISM; PHYSIOLOGY;

ADULT; BONE MARROW; BONE MARROW CELLS; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SELF RENEWAL; HUMANS; MESENCHYMAL STROMAL CELLS; PROTEIN PROCESSING, POST-TRANSLATIONAL; RNA INTERFERENCE; SIRTUIN 1; SOXB1 TRANSCRIPTION FACTORS;

EID: 84912060361     PISSN: 10665099     EISSN: 15494918     Source Type: Journal    
DOI: 10.1002/stem.1811     Document Type: Article

References (52)

1. Jaiswal N, Haynesworth SE, Caplan AI, et al. Osteogenic differentiation of purified, culture-expanded human mesenchymal stem cells in vitro. J Cell Biochem 1997; 64: 295-312.
2. Kuznetsov SA, Krebsbach PH, Satomura K, et al. Single-colony derived strains of human marrow stromal fibroblasts form bone after transplantation in vivo. J Bone Miner Res 1997; 12: 1335-1347.
3. Prockop DJ,. Marrow stromal cells as stem cells for nonhematopoietic tissues. Science 1997; 276: 71-74.
4. Pittenger MF, Mackay AM, Beck SC, et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999; 284: 143-147.et al.
5. Jiang Y, Jahagirdar BN, Reinhardt RL, et al. Pluripotency of mesenchymal stem cells derived from adult marrow. Nature 2002; 418: 41-49.
6. Yoo JU, Barthel TS, Nishimura K, et al. The chondrogenic potential of human bone-marrow-derived mesenchymal progenitor cells. J Bone Joint Surg Am 1998; 80: 1745-1757.
7. Johnstone B, Hering TM, Caplan AI, et al. In vitro chondrogenesis of bone marrow-derived mesenchymal progenitor cells. Exp Cell Res 1998; 238: 265-272.
8. Lazarus HM, Haynesworth SE, Gerson SL, et al. Ex vivo expansion and subsequent infusion of human bone marrow-derived stromal progenitor cells (mesenchymal progenitor cells): Implications for therapeutic use. Bone Marrow Transplant 1995; 16: 557-564.
9. Yoon DS, Kim YH, Jung HS, et al. Importance of Sox2 in maintenance of cell proliferation and multipotency of mesenchymal stem cells in low-density culture. Cell Prolif 2011; 44: 428-440.
10. Ksiazek K,. A comprehensive review on mesenchymal stem cell growth and senescence. Rejuvenation Res 2009; 12: 105-116.
11. Rombouts WJ, Ploemacher RE,. Primary murine MSC show highly efficient homing to the bone marrow but lose homing ability following culture. Leukemia 2003; 17: 160-170.
12. Boiani M, Scholer HR,. Regulatory networks in embryo-derived pluripotent stem cells. Nat Rev Mol Cell Biol 2005; 6: 872-884.
13. Boyer LA, Lee TI, Cole MF, et al. Core transcriptional regulatory circuitry in human embryonic stem cells. Cell 2005; 122: 947-956.
14. Pierantozzi E, Gava B, Manini I, et al. Pluripotency regulators in human mesenchymal stem cells: Expression of NANOG but not of OCT-4 and SOX-2. Stem Cells Dev 2011; 20: 915-923.et al.
15. Liu TM, Wu YN, Guo XM, et al. Effects of ectopic Nanog and Oct4 overexpression on mesenchymal stem cells. Stem Cells Dev 2009; 18: 1013-1022.
16. Tsai CC, Su PF, Huang YF, et al. Oct4 and Nanog directly regulate Dnmt1 to maintain self-renewal and undifferentiated state in mesenchymal stem cells. Mol Cell 2012; 47: 169-182.
17. Seo E, Basu-Roy U, Gunaratne PH, et al. SOX2 regulates YAP1 to maintain stemness and determine cell fate in the osteo-adipo lineage. Cell Rep 2013; 3: 2075-2087.
18. Lengner CJ, Camargo FD, Hochedlinger K, et al. Oct4 expression is not required for mouse somatic stem cell self-renewal. Cell Stem Cell 2007; 1: 403-415.
19. Jaganathan BG, Bonnet D,. Human mesenchymal stromal cells senesce with exogenous OCT4. Cytotherapy 2012; 14: 1054-1063.
20. Niwa H,. How is pluripotency determined and maintained? Development 2007; 134: 635-646.
21. Basu-Roy U, Ambrosetti D, Favaro R, et al. The transcription factor Sox2 is required for osteoblast self-renewal. Cell Death Differ 2010; 17: 1345-1353.
22. Park SB, Seo KW, So AY, et al. SOX2 has a crucial role in the lineage determination and proliferation of mesenchymal stem cells through Dickkopf-1 and c-MYC. Cell Death Differ 2012; 19: 534-545.
23. Baltus GA, Kowalski MP, Zhai H, et al. Acetylation of sox2 induces its nuclear export in embryonic stem cells. Stem Cells 2009; 27: 2175-2184.
24. Yuan HF, Zhai C, Yan XL, et al. SIRT1 is required for long-term growth of human mesenchymal stem cells. J Mol Med (Berl) 2012; 90: 389-400.
25. Simic P, Zainabadi K, Bell E, et al. SIRT1 regulates differentiation of mesenchymal stem cells by deacetylating beta-catenin. EMBO Mol Med 2013; 5: 430-440.
26. Shakibaei M, Shayan P, Busch F, et al. Resveratrol mediated modulation of Sirt-1/Runx2 promotes osteogenic differentiation of mesenchymal stem cells: Potential role of Runx2 deacetylation. PLoS One 2012; 7: e35712.
27. Han MK, Song EK, Guo Y, et al. SIRT1 regulates apoptosis and Nanog expression in mouse embryonic stem cells by controlling p53 subcellular localization. Cell Stem Cell 2008; 2: 241-251.
28. Zhang ZN, Chung SK, Xu Z, et al. Oct4 maintains the pluripotency of human embryonic stem cells by inactivating p53 through Sirt1-mediated deacetylation. Stem Cells 2014; 32: 157-165.
29. Kim YH, Yoon DS, Kim HO, et al. Characterization of different subpopulations from bone marrow-derived mesenchymal stromal cells by alkaline phosphatase expression. Stem Cells Dev 2012; 21: 2958-2968.
30. Lee S, Yoon DS, Paik S, et al. MicroRNA-495 inhibits chondrogenic differentiation in human mesenchymal stem cells by targeting Sox9. Stem Cells Dev 2014; 23: 1798-1808.
31. Yoon DS, Kim YH, Lee S, et al. Interleukin-6 induces the lineage commitment of bone marrow-derived mesenchymal multipotent cells through down-regulation of Sox2 by osteogenic transcription factors. FASEB J 2014; 28: 3273-3286.
32. Liedtke S, Stephan M, Kogler G,. Oct4 expression revisited: Potential pitfalls for data misinterpretation in stem cell research. Biol Chem 2008; 389: 845-850.
33. Fan YX, Gu CH, Zhang YL, et al. Oct4 and Sox2 overexpression improves the proliferation and differentiation of bone mesenchymal stem cells in Xiaomeishan porcine. Genet Mol Res 2013; 12: 6067-6079.
34. Sinclair DA, Guarente L,. Unlocking the secrets of longevity genes. Sci Am 2006; 294: 48-51, 54-47.
35. Miyagi S, Kato H, Okuda A,. Role of SoxB1 transcription factors in development. Cell Mol Life Sci 2009; 66: 3675-3684.
36. Chew JL, Loh YH, Zhang W, et al. Reciprocal transcriptional regulation of Pou5f1 and Sox2 via the Oct4/Sox2 complex in embryonic stem cells. Mol Cell Biol 2005; 25: 6031-6046.
37. Vanhaecke T, Papeleu P, Elaut G, et al. Trichostatin A-like hydroxamate histone deacetylase inhibitors as therapeutic agents: Toxicological point of view. Curr Med Chem 2004; 11: 1629-1643.
38. Li Z, Liu C, Xie Z, et al. Epigenetic dysregulation in mesenchymal stem cell aging and spontaneous differentiation. PLoS One 2011; 6: e20526.
39. Tsuruzoe S, Ishihara K, Uchimura Y, et al. Inhibition of DNA binding of Sox2 by the SUMO conjugation. Biochem Biophys Res Commun 2006; 351: 920-926.
40. Zhao HY, Zhang YJ, Dai H, et al. CARM1 mediates modulation of Sox2. PLoS One 2011; 6: e27026.
41. Finkel T, Deng CX, Mostoslavsky R,. Recent progress in the biology and physiology of sirtuins. Nature 2009; 460: 587-591.
42. Brooks CL, Gu W,. How does SIRT1 affect metabolism, senescence and cancer? Nat Rev Cancer 2009; 9: 123-128.
43. Signorelli P, Ghidoni R,. Resveratrol as an anticancer nutrient: Molecular basis, open questions and promises. J Nutr Biochem 2005; 16: 449-466.
44. Joe AK, Liu H, Suzui M, et al. Resveratrol induces growth inhibition, S-phase arrest, apoptosis, and changes in biomarker expression in several human cancer cell lines. Clin Cancer Res 2002; 8: 893-903.
45. Pizarro JG, Verdaguer E, Ancrenaz V, et al. Resveratrol inhibits proliferation and promotes apoptosis of neuroblastoma cells: Role of sirtuin 1. Neurochem Res 2011; 36: 187-194.et al.
46. Valenzano DR, Terzibasi E, Genade T, et al. Resveratrol prolongs lifespan and retards the onset of age-related markers in a short-lived vertebrate. Curr Biol 2006; 16: 296-300.
47. Dai Z, Li Y, Quarles LD, et al. Resveratrol enhances proliferation and osteoblastic differentiation in human mesenchymal stem cells via ER-dependent ERK1/2 activation. Phytomedicine 2007; 14: 806-814.
48. Tseng PC, Hou SM, Chen RJ, et al. Resveratrol promotes osteogenesis of human mesenchymal stem cells by upregulating RUNX2 gene expression via the SIRT1/FOXO3A axis. J Bone Miner Res 2011; 26: 2552-2563.
49. Zhou H, Shang L, Li X, et al. Resveratrol augments the canonical Wnt signaling pathway in promoting osteoblastic differentiation of multipotent mesenchymal cells. Exp Cell Res 2009; 315: 2953-2962.
50. Backesjo CM, Li Y, Lindgren U, et al. Activation of Sirt1 decreases adipocyte formation during osteoblast differentiation of mesenchymal stem cells. Cells Tissues Organs 2009; 189: 93-97.
51. Peltz L, Gomez J, Marquez M, et al. Resveratrol exerts dosage and duration dependent effect on human mesenchymal stem cell development. PLoS One 2012; 7: e37162.
52. Ding DF, Li XF, Xu H, et al. Mechanism of resveratrol on the promotion of induced pluripotent stem cells. J Integr Med 2013; 11: 389-396.